Comparison
Ganirelix vs. Bremelanotide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
123246-29-7
189691-06-3
Molecular weight
1570.3 g/mol
1025.18 g/mol
Half-life
no data
2.7 h
Sequence
no data
Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OHMechanism of action
Ganirelix
Ganirelix competitively and reversibly binds the pituitary GnRH receptor, rapidly suppressing LH (and, less so, FSH) release — without the initial hormone 'flare' of GnRH agonists.
Bremelanotide
Bremelanotide is a cyclic peptide that binds non-selectively to melanocortin receptors (MC1R through MC5R) — with highest affinity at MC4R in the central nervous system. The precise role of MC4R activation in sexual behaviour is not fully understood; animal data show effects on hypothalamic circuits. Peripheral effects (blood pressure, hyperpigmentation) are attributed to MC1R/MC2R.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
1
5
of which in humans
1
5
Effects recorded
2
3
Open conflicts
0
1
Documented adverse events
1
2
Legal status
Full entries
Frequently asked questions
- What is the difference between Ganirelix and Bremelanotide?
- Ganirelix is classified as "Research other", while Bremelanotide is classified as "Research other". Ganirelix: Ganirelix is a synthetic decapeptide and GnRH antagonist. In assisted reproduction (IVF) it prevents the premature LH surge during controlled ovarian stimulation. Bremelanotide: Synthetic cyclic heptapeptide acting as a non-selective melanocortin-receptor agonist. FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in pre-menopausal women. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Ganirelix or Bremelanotide?
- The highest available evidence level is "Human RCT" for Ganirelix and "Human RCT" for Bremelanotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Ganirelix and Bremelanotide in Germany and the United States?
- Germany: Ganirelix — Prescription, Bremelanotide — Unapproved. United States: Ganirelix — Prescription, Bremelanotide — Prescription. These are factual summaries with source and review date on the individual pages.